Indian IT giant investigates link to M&S cyber-attack
Tata Consultancy Services (TCS) has provided services to M&S for more than a decade.
Earlier this week, M&S said the hackers who had brought huge disruption to the retailer had managed to gain access to their systems via a 'third party' – a company working alongside it – rather than accessing those systems directly.
M&S and TCS have both declined to comment.
The FT, which first reported the story, cited people close to the investigation who said it was hoped the inquiry would be concluded by the end of the month.
It is not clear when TCS launched its investigation.
Customers have not been able to buy items on the M&S website since the end of April.
It said earlier this week that online services should see a gradual return to normal over the coming weeks, but some level of disruption would continue until July.
M&S estimates that the cyber-attack will hit this year's profits by around £300m.
Police are focusing on a notorious group of English-speaking hackers, known as Scattered Spider, the BBC has learned.
The same group is believed to have been behind attacks on the Co-op and Harrods, but it was M&S that suffered the biggest impact.
TCS says it has over 607,000 employees across the world and is the lead sponsor of three prestigious marathons – New York, London and Sydney.
On its website, TCS said it worked with M&S on Sparks, its customer reward scheme. Read More Cryptoassets increase risk in developing economies, study says
In 2023, TCS and M&S won the Retail Partnership of the Year award at the Retail Systems Awards.
TCS has a portfolio of well-known clients including the Co-op, according to its website.
There is no indication if the internal probe is also looking at the hack on the Co-Op.
TCS also counts easyjet, Nationwide and Jaguar Land Rover among its many clients.
Earlier this week, M&S chief executive Stuart Machin said: 'Over the last few weeks, we have been managing a highly sophisticated and targeted cyber-attack, which has led to a limited period of disruption.'
In a media call on Wednesday, he did not respond to a question about whether the company had paid a ransom as part of the process.
READ SOURCE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Business Insider
3 hours ago
- Business Insider
Seeking Up to 11% Dividend Yield? Analysts Pick 2 Dividend Stocks to Buy
The stock markets hit a low in April, and have since shown a tremendous rebound – but can it last? That's the question investors are wrestling with now, and it seems they are getting some pointers from Barry Bannister, chief equity strategist at Stifel. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bannister believes that the stock rebound – fueled by the AI boom, and the rush of capital spending as companies moved to get ahead of tariffs during the first half of the year – is simply not sustainable, noting that the S&P 500 is trading at a historically high valuation. 'Valuation doesn't matter until it does,' Bannister says, and adds that he can see the S&P 500 index falling as low as 5,500, for a drop of nearly 15%. Despite this downbeat outlook, Bannister is not recommending that investors get out of the market. He's recommending, instead, that investors make defensive moves to seek protection from a turndown. That outlook will naturally push investors' attention toward high-yield dividend stocks. These represent the classic defensive play, and for good reason. Dividends offer investors a steady income stream, and high-yield dividends guarantee a sound return well above the rate of inflation. Against this backdrop, we've opened up the TipRanks database to take a look at two dividend stocks that the analysts are picking out as Buys. These are dividend stocks offering yields as high as 11%, a solid return by any standard. Let's give them a closer look. Ellington Financial (EFC) The first stock we'll look at here, Ellington Financial, is a REIT, a real estate investment trust. These companies operate through strategic investments, mainly in real properties, mortgages, and mortgage-related assets, in both the residential and commercial spheres. Ellington's particular strategy involves building a diverse investment portfolio, made up of both residential and commercial mortgage loans, along with residential and commercial mortgage-backed securities, as well as other assets, including consumer loans, collateralized loan obligations, and various mortgage-related and non-mortgage-related securities and derivatives. Ellington's main goal in building this portfolio is to generate returns for its stockholders – in the company's words, 'attractive risk-adjusted total returns.' Ellington's strategy is opportunistic, targeting remunerative investments, but the company takes a defensive posture as well, investing across a wide range of sectors to capitalize on disparate strengths in its portfolio and making risk management a key part of its activities. As of June 30 this year, Ellington Financial had a total of $16.1 billion in assets under management. This portfolio is managed by an experienced team – the company's portfolio managers average 30 years of industry experience. These features of Ellington's business, its focus on shareholder returns and the long experience of its management team, have helped the company to cement a reputation as a high-quality dividend payer. The company's dividend features a high yield, as well as a monthly payment schedule. The last declaration, made on August 7 for a September 30 payment, was for 13 cents per common share. That dividend annualizes to $1.56 per share and gives a powerful forward yield of 11.5%. In its 2Q25 financial report, Ellington listed its quarterly adjusted distributable earnings as $45 million, or 47 cents per share. This was more than enough to fully cover the dividend, which currently comes to 39 cents per quarter. Covering this stock for Piper Sandler, following the Q2 print, analyst Crispin Love laid out a clear case for investors to go long on EFC: 'Ellington posted a beat this quarter with strength in both its credit and Longbridge strategies. In April around the market volatility, Ellington saw opportunities to deploy capital in its core credit strategies and also saw attractive opportunities in securities. Following the volatility, EFC was able to complete six securitizations in the quarter, which is a record for the company. The company also experienced success from its loan originator platforms, and we would not be surprised to see more partnerships and equity stakes over the intermediate term. Specifically, if there is GSE reform it could limit Fannie and Freddie's footprint and provide opportunities for Ellington to grow further in the non-QM space which is an area of expertise. Management was positive on the forward earnings trajectory and continued coverage of the $0.39 dividend.' These comments back up Love's Overweight (i.e., Buy) rating, and his $14.50 price target implies a gain of 5.5% in the next 12 months. But with the dividend yield included the upside can reach 17%. (To watch Love's track record, click here) There are 7 recent analyst reviews on record for Ellington, and the 5-to-2 split, favoring Buys over Holds, supports a Moderate Buy consensus rating. The Street's average target of $14.25 is the same as Love's. (See EFC stock forecast) LPG) Our world runs on energy, and the next company on our list here, Dorian LPG, is a leading carrier of that energy. Dorian is an owner/operator of very large gas carriers, VLGC vessels, which are the largest ocean-going carriers of liquefied petroleum gas, an important fuel in the world economy. The core of Dorian's business is its fleet of ships. The company maintains a modern fleet of VLGCs, with the oldest ship dating back to 2007. Most of the company's vessels were launched much more recently, in 2015, and the newest vessels in the fleet were launched in 2023. The vessels have an average age of 8 years, and their aggregate carrying capacity is some 2.1 million cubic meters of LPG. Dorian owns 21 of its ships, and operates the others on charter agreements. Most of the ships in Dorian's fleet are flagged in the Bahamas, although several are flagged in Liberia, Madeira, or Panama. The company is headquartered in Connecticut and has offices in Copenhagen and Athens. The international office footprint, and varying flags, are also common on the world's oceangoing cargo carriers. Dorian finished its last quarter, fiscal 1Q26 (June quarter), with just over $278 million in cash and liquid assets. The company pays an irregular dividend, meaning it has no obligation to pay out, or to maintain dividend payments at any level; while this poses risks for investors, it also allows the company to adjust the dividend to keep them affordable. That said, Dorian has been paying out dividends since 2021, and has not missed a quarterly payment in that time. The most recent dividend, declared on August 1 for payment on the 27th, set the rate at 60 cents per share. This dividend annualizes to $2.40 per common share, and gives a forward yield of 8%. On the financial side, Dorian generated $84.2 million in total revenues during its fiscal first quarter, a total that was down 26% year-over-year and fell shy of analyst expectations by $2.3 million. Additionally, adj. EPS of $0.27 missed the Street's forecast by $0.34. Despite the weak report, Jefferies analyst Omar Nokta remains bullish on the stock, writing: 'Dorian reported softer than expected fiscal 1Q26 results mainly due to higher G&A and higher drydocking costs, and also slightly lower than expected revenues… We view this earnings miss as a one-off… VLGC spot rates have strengthened materially and are at 2025 highs, setting up a very strong upcoming result next quarter and potentially a higher dividend… The company remains dedicated to returning capital to shareholders, and its shares trade at a discount to our NAV valuation of $33.80/sh… Dorian is our top pick in the LPG space, and we remain constructive on the name.' The 5-star analyst rates LPG shares as a Buy, and gives them a price target of $35, pointing toward a one-year gain of 16.5%. (To watch Nokta's track record, click here) There are only 2 recent analyst reviews on file for Dorian, but both are positive, giving the stock its Moderate Buy consensus rating. The shares are priced at $30.06, and the $33 average price target implies a 10% upside potential on the one-year horizon. (See LPG stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
3 hours ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, August 17, 2025
Everything to Know about Macro and Markets Stocks ended the week on a soft note, still managing to lock in back-to-back weekly gains. The S&P 500 (SPX) rose 0.94% for the week, and the Nasdaq-100 (NDX) inched up 0.43%. The Dow Jones Industrial Average (DJIA) was the standout, delivering a weekly gain of 1.74%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. A Week of Contrasts After a red Monday, all three major indexes reached all-time highs on Tuesday. This followed in-line CPI data, which bolstered bets that the Fed would deliver its first rate cut of 2025 in September – traders have priced in nearly a 100% chance of a 25-bps easing. Stocks extended gains on Wednesday: the S&P 500 and Nasdaq hit new ATHs again amid remarks from Treasury Secretary Scott Bessent urging a 50-bps cut based on downward revisions in payroll data. Wall Street analysts began forecasting up to three cuts this year, citing a softer labor market, limited tariff pass-through to consumer prices, and the appointment of Trump's temporary Fed board pick. But those forecasts were questioned Thursday when PPI, which tracks wholesale price trends, came in hotter than expected, denting sentiment and clouding the Fed outlook. Other economic reports pulled markets in opposing directions: July's industrial production was lackluster – although not recession-bellwether weak – while retail sales beat forecasts, underscoring resilient consumer demand despite high borrowing costs. Meanwhile, the UoM consumer sentiment unexpectedly slipped and inflation expectations rose, muddying the outlook for Fed cuts in September. On Friday, the Dow's gains were dominated by UnitedHealth's surge following Berkshire Hathaway's disclosure of a large stake in the embattled healthcare giant. Meanwhile, the S&P 500 and Nasdaq's advances were tempered by tech weakness amid cautious corporate outlooks and persistent tariff concerns, particularly in semiconductors. This week featured leadership rotation: healthcare and small-caps rose, while semiconductors and tech lagged under the weight of inflation and trade worries. With mixed inflation and consumer data re-injecting uncertainty into the Fed policy outlook, all eyes now turn to Jackson Hole. Jerome Powell's speech on August 22 is the marquee event, expected to instantly influence markets. A dovish tone could broaden the rally, boosting small caps, rate-sensitive areas, and tech. A hawkish stance – highlighting inflation risks or caution – could trigger sharp corrections and volatility, especially in growth and rate-sensitive sectors. Adaptability, Profitability, and Capex Economic data remains mixed – but corporate signals are broadly bullish, despite overbought pockets and uneven strength. As Benjamin Graham famously said, 'in the short run, the market is a voting machine but in the long run, it is a weighing machine.' Prices may swing on sentiment or episodic events, but over time, earnings growth is what ultimately matters. On that front, Q2 2025 earnings have been compelling: over 90% of companies have reported, with average EPS growth near 11% year-over-year – versus expectations of 3-4% at the quarter's start. This follows a similar pattern seen in Q1 season. In the second quarter, 84% beat expectations, surprising by an average of 9%. U.S. companies' adaptability – particularly in counteracting tariff shocks – is helping shield both the economy and equity markets. Notably, S&P 500 forward 12-month EPS estimates are now at record highs, driven largely by tech megacap profitability and reinvestment. AI capex alone has contributed more to GDP growth in H1 2025 than consumer spending. While over the long term, consumer demand has been the undisputed engine of growth – megacaps' AI and cloud investment plans signal continued acceleration of their role in fueling the expansion. The sterling Q2 earning-growth results have broadly dispelled investor fears over trade policies weighing on the economy and corporate performance. FactSet reports that 'recession' mentions in earnings calls dropped nearly 70% from Q1 2025, hitting their lowest levels since 2005. Polymarket's 2025 recession odds plunged from over 65% in May to 12%, signaling there's no longer a belief that levies on imports mean a recession is imminent. Tariffs still get airtime, even if much less than in Q1 – but the C-suite and market participants now see them as manageable. Factors such as lower energy prices and decelerating housing-related inflation are further diluting the tariff impact. Strategists now expect any tariff impact on inflation to be delayed and muted, with economic growth holding relatively firm. Stocks That Made the News ▣ UnitedHealth (UNH) soared over 22% on the week after Berkshire Hathaway ($BRK.B) disclosed a new stake in the beaten-down healthcare provider. Warren Buffett's conglomerate acquired 5.04 million UNH shares valued at $1.57 billion. ▣ Applied Materials (AMAT) plunged 13% despite delivering record performance last quarter, as the chip equipment provider offered weaker-than-expected guidance amid weak China demand, stalled export license approvals, and uneven orders. Despite the near-term challenges, the company remains optimistic about mid-single-digit growth for fiscal 2025, driven by investments in U.S. manufacturing and advancements in semiconductor technology. ▣ Intel (INTC) was on the winning side of the semi trade, popping by over 22% on the week following reports that the Trump administration was mulling the potential for the government to take a stake in the embattled company to aid domestic chip manufacturing expansion. ▣ Palantir Technologies (PLTR) declined after Andrew Left, head of short-selling firm Citron Research, said he was betting against the company in light of its lofty valuation, which he called 'absurd.' ▣ Amazon (AMZN) rallied as analysts applauded analysts applauding its expansion into free same-day grocery delivery nationwide for Prime members. Evercore ISI said that this expansion deepens Amazon's customer engagement by strengthening a high-frequency purchase category into the Prime ecosystem, increasing stickiness and customer lifetime value. ▣ Oracle (ORCL) also bucked the down trend on Friday, rallying on news of expanded partnership with Alphabet's (GOOGL) Google Cloud. Under the collaboration, Oracle will integrate Google's Gemini AI models into Oracle Cloud Infrastructure (OCI). This allows Oracle's enterprise customers to access Google's Gemini AI capabilities – including multimodal understanding, coding assistance, and workflow automation – via OCI services, enhancing productivity and workflow automation. The deal – similar to one that Oracle struck with Elon Musk's xAI back in June – is expected to significantly broaden Oracle's AI offerings, advancing its strategy of offering a menu of AI options rather than trying to push its own technology exclusively. The Q2 2025 earnings season is winding down, but several notable releases are still scheduled for this week. These include: Palo Alto Networks (PANW), Home Depot (HD), Medtronic (MDT), Keysight Technologies (KEYS), TJX Companies (TJX), Lowe's (LOW), Analog Devices (ADI), Target (TGT), Walmart (WMT), Intuit (INTU), Workday (WDAY), and Ross Stores (ROST).
